2631 Early onset of efficacy with Atogepant for the preventive treatment of chronic migraine: results from the PROGRESS trial

ObjectivesEvaluate the time course of efficacy of atogepant for the preventive treatment of Chronic Migraine (CM).MethodsPROGRESS was a phase 3 trial which assessed the efficacy and safety of atogepant in patients with CM. This analysis evaluated the change from baseline in mean monthly migraine day...

Full description

Saved in:
Bibliographic Details
Published in:BMJ neurology open 2023-08, Vol.5 (Suppl 1), p.A24-A24
Main Authors: Ailani, Jessica, Reuter, Uwe, Klein, Brad C, Yu, Sung Yun, Nagy, Krisztian, Go, Hua, Watts, Kate, Trugman, Joel
Format: Article
Language:English
Subjects:
Migraine
Poster Abstract
Online Access:Request full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:ObjectivesEvaluate the time course of efficacy of atogepant for the preventive treatment of Chronic Migraine (CM).MethodsPROGRESS was a phase 3 trial which assessed the efficacy and safety of atogepant in patients with CM. This analysis evaluated the change from baseline in mean monthly migraine days (MMDs) during 4-week intervals, change in weekly migraine days during weeks 1–4, and the proportion of participants with a migraine on each day during the first 7 days of treatment.Results755 participants were included. Baseline MMDs ranged from 18.6 to 19.2. During weeks 1–4 of treatment,mean changes in MMDs were −6.6 for atogepant 30mg BID, −6.2 for atogepant 60mg QD, and −3.7 for placebo (P
ISSN:2632-6140
DOI:10.1136/bmjno-2023-ANZAN.63